Dopavision Presented Key Data from its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference
— First Data Presentation: Friday’s presentation marked the first public disclosure of the 6-month data from the MyopiaX-1 clinical trial in children with myopia (NCT04967287). — MyopiaX Clinical Outcomes: MyopiaX demonstrated positive proof of concept at six months, showing promise for future clinical studies. — Final Trial Visits:The 12-month MyopiaX-1 clinical trial is ongoing at sites […]
Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia
— Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX’s excellent safety and tolerability profile with no untoward safety events. — Novel Approach: Dopavision’s approach to delivering targeted photobiomodulation to the eye shows signals of clinical effect on the rate of myopia progression. — New Alternative: The intervention delivered in an easy to […]
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
– MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression – First data readout expected in Q1/ 2024 with study completion planned for September 2024 Berlin, Germany, September 26, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful […]
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
– First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally – Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom Berlin, Germany, June 28, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced an update on its […]
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
– Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 — Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today announced the appointment of Prof. Dr. Jens Ellrich as Chief Scientific Officer. Jens Ellrich brings a wealth of scientific knowledge and extensive experience in […]
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board
– Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 — Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record […]
Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer
– Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital therapeutic for childhood myopia Berlin, Germany, May 25, 2022 — Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company’s Chief Executive Officer. […]
Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials
– Seventure Partners and Novartis Pharmaceuticals join as new investors – Transformative treatment for millions of children with myopia Berlin, Germany, July 14, 2021 — Dopavision, a company pioneering the development of digital therapeutics, today announced the closing of a €12 million Series A financing round. Seventure Partners led the round and was joined by […]
Digital health startup Dopavision raises €1.2 million seed investment
Fighting the global myopia epidemic with digital technology: Dopavision, a Berlin-based digital health startup, is developing an innovative treatment for one of the largest medical needs in the world. After winning German government funding of € 1.4 million in 2018, Dopavision has successfully attracted venture investors for a seed investment of € 1.2 million. Lead […]